San Diego, CA (PRWEB) May 20, 2013
Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Robert L. Wilensky, MD, Professor of Medicine and Director of Interventional Cardiology Research at the University of Pennsylvania has agreed to join the Scientific and Medical Advisory Board for Stemedica’s Cardiology Division.
At the University of Pennsylvania, Dr. Wilensky divides his time between the cardiac catheterization laboratories and the translational animal laboratory. His research interests include acute coronary syndromes, diagnosis and treatment of vulnerable coronary lesions and stem cell therapy for decreased left ventricular function and coronary artery disease.
Stephen Epstein, MD, Chairman of Stemedica’s Cardiology Division Scientific and Medical Advisory Board commented, “Dr. Wilensky’s strong interest and expertise in both interventional cardiology and translational medicine, most notably with stem cells, parallels and strongly supports the direction we are taking with Stemedica.”
Dr. Wilensky received his MD degree with distinction from the University of Amsterdam. His internship and residency in Internal Medicine was obtained at the Georgetown University Medical Center in Washington, DC. His fellowship in Cardiology was at the Krannert Institute of Cardiology, Indiana University, where he was Chief Fellow and later Assistant Professor of Medicine. He joined the faculty of the University of Pennsylvania in 1996.
Dr. Wilensky has been an active organizer of, and participant in, many international cardiology symposia, including the Cardiovascular Revascularization Therapies meetings and Transcatheter Therapeutics Meetings. He has lectured both domestically and internationally. He is a Fellow of the American College of Cardiology and the American Heart Association. He is the author or co-author of over 165 papers and has been issued three US patents. His pioneer work on comparing different methods of stem cell delivery in acute myocardial infarction pig model has made a significant contribution to the understanding of the mechanism of action of mesenchymal stem cells.
Sergey Sikora, PhD, President of Stemedica’s Cardiovascular Division noted, “As we explore the best delivery systems for cardiac stem cell treatment, we will draw upon Dr. Wilensky’s experience in this key area. He will be an invaluable contributor in the planning of future pre-clinical and clinical studies in the area of acute myocardial infarction.”
Maynard Howe, Ph.D., Chief Executive Officer, and Vice Chairman of Stemedica commented, “We are delighted to have another world-class cardiac clinician and researcher join our team. We look forward to working with Dr. Wilensky.”
Stemedica currently has three FDA-approved clinical trials underway in ischemic stroke, acute myocardial infarct and cutaneous photoaging.
About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
For more information regarding Stemedica Cell Technologies, Inc., contact Dave McGuigan at dmcguigan(at)stemedica(dot)com.